|
Cold Spring Harbor Laboratory Meetings
mouse pancreatic tumor 3d organoids Mouse Pancreatic Tumor 3d Organoids, supplied by Cold Spring Harbor Laboratory Meetings, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+organoids/pdac+organoids/pmc10325911-71-0-11 Average 90 stars, based on 1 article reviews
mouse pancreatic tumor 3d organoids - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Jackson Laboratory
mouse pdac organoids ![]() Mouse Pdac Organoids, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+organoids/mouse+pdac+organoids/pmc11448066-110-18-36 Average 90 stars, based on 1 article reviews
mouse pdac organoids - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Corning Life Sciences
metabolomics assay pdac organoids in matrigel ![]() Metabolomics Assay Pdac Organoids In Matrigel, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+organoids/metabolomics+assay+pdac+organoids+in+matrigel/pm37597521-230-2-8 Average 90 stars, based on 1 article reviews
metabolomics assay pdac organoids in matrigel - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Cold Spring Harbor Laboratory Meetings
pdac organoid lines ![]() Pdac Organoid Lines, supplied by Cold Spring Harbor Laboratory Meetings, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+organoids/pdac+organoid+lines/10__1515_slash_iss___2020___2001-937-0-17 Average 90 stars, based on 1 article reviews
pdac organoid lines - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Corning Life Sciences
pdac organoids in matrigel 356231 ![]() Pdac Organoids In Matrigel 356231, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+organoids/pdac+organoids+in+matrigel+356231/pmc10518604-325-0-4 Average 90 stars, based on 1 article reviews
pdac organoids in matrigel 356231 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Korean Cell Line Bank
living biobank of pdac organoids ![]() Living Biobank Of Pdac Organoids, supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+organoids/living+biobank+of+pdac+organoids/pmc11467084-338-2-9 Average 90 stars, based on 1 article reviews
living biobank of pdac organoids - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Cold Spring Harbor Laboratory Meetings
orthotopically grafted organoid (ogo) model of pancreatic ductal adenocarcinoma (pdac) ![]() Orthotopically Grafted Organoid (Ogo) Model Of Pancreatic Ductal Adenocarcinoma (Pdac), supplied by Cold Spring Harbor Laboratory Meetings, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+organoids/orthotopically+grafted+organoid++ogo++model+of+pancreatic+ductal+adenocarcinoma++pdac+/10__1038_slash_s41684___020___0631___0-2-16-2 Average 90 stars, based on 1 article reviews
orthotopically grafted organoid (ogo) model of pancreatic ductal adenocarcinoma (pdac) - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Korean Cell Line Bank
pdac organoids ![]() Pdac Organoids, supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+organoids/pdac+organoids/pm38619751-300-4-9 Average 90 stars, based on 1 article reviews
pdac organoids - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Metabolon Inc
metabolon based energy metabolism detection pdac organoids inmatrigel ![]() Metabolon Based Energy Metabolism Detection Pdac Organoids Inmatrigel, supplied by Metabolon Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+organoids/based+detection+energy+inmatrigel+metabolism+metabolon+organoids+pdac/pm37597521-245-0-0 Average 86 stars, based on 1 article reviews
metabolon based energy metabolism detection pdac organoids inmatrigel - by Bioz Stars,
2026-11
86/100 stars
|
Buy from Supplier |
|
Cold Spring Harbor Laboratory Meetings
human pdac organoid culture ![]() Human Pdac Organoid Culture, supplied by Cold Spring Harbor Laboratory Meetings, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+organoids/culture+human+organoid+pdac/pm38716830-149-22-12 Average 86 stars, based on 1 article reviews
human pdac organoid culture - by Bioz Stars,
2026-11
86/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment
doi: 10.1186/s13046-024-03201-w
Figure Lengend Snippet: CALB2 collaborates with hypoxia to activate an inflammatory fibroblast phenotype and enhances PDAC migration and growth. ( A ) Heatmap illustrating the gene set variation analyses (GSVA) score of the indicated CAF subpopulations using human scRNA-seq data. ( B ) Deciphering the differentiating signatures by trajectory inferences. (i-ii) Cell trajectory of PSCs, CALB2 − and CALB2 + CAF subpopulations. (iii) CALB2 expression in the process of CAF differentiation. Black arrows indicate the direction of pseudotime in trajectory plot. ( C-D ) PSCs were exposed to normoxia (20% O 2 ) or hypoxia (1% O 2 ) for 72 h, followed by RT-qPCR analysis ( C ) and western blotting ( D ). ( E - G ) PSCs were subjected to stable CALB2 overexpression (CALB2-OE), followed by examining cell growth using proliferation assay ( E ), the indicated proteins using western blotting ( F ), and IL6 production using ELISA ( G ). ( H ) Schematic diagram showing the establishment of the transwell co-culture system of organoid growth (left) or cell migration (right). ( I ) Transwell co-culture assays of growth of PDAC patient-derived organoids (PDOs) co-cultured with Control or CALB2 + CAFs for 5 days. ( J ) Transwell co-culture assays of migration of BxPC-3 and PANC-1 cells co-cultured with Control or CALB2 + CAFs for 24 h. ( K-M ) PDAC PDOs were orthotopically transplanted with Control or CALB2 + CAFs into the pancreas of NSG mice for 5 weeks ( n = 5), followed by examining tumor growth ( K ), ex vivo pancreas imaging ( L ), representative H&E staining, and IHC of FAP and CALB2 ( M ). Scale bars, 500 μm ( I ), 100 μm ( J ), 1 cm ( K ), and 200 μm ( M ). Error bars, mean ± SD; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant; by Student’s t test
Article Snippet:
Techniques: Migration, Expressing, Quantitative RT-PCR, Western Blot, Over Expression, Proliferation Assay, Enzyme-linked Immunosorbent Assay, Co-Culture Assay, Derivative Assay, Cell Culture, Control, Ex Vivo, Imaging, Staining
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment
doi: 10.1186/s13046-024-03201-w
Figure Lengend Snippet: CALB2 is upregulated in PDAC cells through IL6-STAT3 inflammatory signaling pathway. ( A-B ) PANC-1 cells were co-cultured with CALB2 + CAFs or control CAFs for 72 h, followed by western blotting ( A ) and RT-qPCR analysis ( B ). ( C-D ) PANC-1 cells were treated with 100 ng/mL rhIL6 over the time, followed by western blotting ( C ) and RT-qPCR analysis ( D ). ( E ) Measurement of IL6 concentration in the co-culture system containing CALB2 + CAFs or control CAFs using ELISA. ( F ) PANC-1 cells were pre-treated with 2.5 μg/mL Tocilizumab (IL6R neutralizing antibody) for 24 h, then cultured with CALB2 + CAFs or treated with 100 ng/mL rhIL6 for 48 h, followed by western blotting. ( G-H ) PANC-1 ( G ) or BxPC-3 ( H ) cells were treated with the indicated concentration of stattic (STAT3 inhibitor) and 100 ng/mL rhIL6 for 48 h, followed by western blotting. ( I ) Human PDAC organoids were dissociated into single cells and cultured with the following conditions for 5 days: control CAFs conditioned medium (CM) + DMSO (Control), CALB2 + CAFs CM + DMSO, and CALB2 + CAFs CM + 4 μΜ stattic, followed by microscopic imaging (top left), organoid tissue-based cyclic immunofluorescence to examine CALB2 expression (bottom left) and quantification of organoid growth (right). ( J ) Human PDAC organoids were dissociated into single cells and cultured with CALB2 + CAFs CM + 4 μM stattic or control DMSO for 5 days, and then were treated with control PBS or GEM for 48 h, followed by assaying organoid apoptosis and quantification. ( K - L ) CUT&RUN-qPCR assays showing binding of STAT3 to CALB2 promoter region was significantly enhanced by STAT3 overexpression in PANC-1 cells ( K ), while it was substantially impaired by STAT3 knockdown in CFPAC-1 cells ( L ). ( M ) Sequential deletions for evaluating the transcriptional activity of the CALB2 promoter in PANC-1 cells with or without STAT3 overexpression. ( N ) Relative luciferase activity of luciferase reporter plasmids bearing wild-type (WT) or mutant (MUT) CALB2 promoter in control or STAT3-overexpressing PANC-1 cells. Scale bars, 500 μm ( I top), 100 μm ( I bottom and J ). Error bars, mean ± SD; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant; by one-way ANOVA ( D , I , J , and L ) or Student’s t test ( B , E , K , M , and N )
Article Snippet:
Techniques: Cell Culture, Control, Western Blot, Quantitative RT-PCR, Concentration Assay, Co-Culture Assay, Enzyme-linked Immunosorbent Assay, Imaging, Immunofluorescence, Expressing, Binding Assay, Over Expression, Knockdown, Activity Assay, Luciferase, Mutagenesis
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment
doi: 10.1186/s13046-024-03201-w
Figure Lengend Snippet: Downregulation of CALB2 inhibits epithelial-mesenchymal transition and metastatic outgrowth of PDAC. ( A ) Western blotting of CALB2 expression in human normal pancreatic ductal cells (HPNE), and human primary and metastatic PDAC cell lines. ( B ) The migration ability of control, or CALB2 KD or KO PDAC cells was determined by Transwell assays. ( C-D ) The influence of CALB2 knockdown (KD) or knockout (KO) on the in vitro proliferation ( C ) and sensitivity to gemcitabine ( D ) of PDAC cells was evaluated by CCK8 assays. ( E ) Significantly downregulated pathways (FDR < 0.05 and logFC > 0.5) identified by DAVID analysis of CALB2-KD AsPC-1 cells ( n = 3) compared to control AsPC-1 cells ( n = 3). ( F ) Western blot analysis of E-cadherin and N-cadherin in CALB2-KD AsPC-1 stable cell lines (left) or CALB2-KO CFPAC-1 stable cell lines (right). ( G-H ) IVIS living imaging ( G ), representative bright-field images of liver tissues and ex vivo liver imaging ( H ) after 5 weeks of splenic injection of CALB2-KO or control CFPAC-1 stable cell lines ( n = 4 per group). ( I-J ) Relative expression of epithelial ( I ) and mesenchymal ( J ) genes in liver metastases from CALB2-KO ( n = 3) and control ( n = 4) tumors using RT-qPCR (2 −Δt ). Scale bars, 200 μm ( B ), 1 cm ( H ). Error bars, mean ± SD; * p < 0.05, **p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant; by one-way ANOVA ( B , C , and D ) or Student’s t test ( G , H , I , and J )
Article Snippet:
Techniques: Western Blot, Expressing, Migration, Control, Knockdown, Knock-Out, In Vitro, Stable Transfection, Imaging, Ex Vivo, Injection, Quantitative RT-PCR
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment
doi: 10.1186/s13046-024-03201-w
Figure Lengend Snippet: Combination of CXCL14 neutralizing antibody with gemcitabine effectively hinders CALB2-mediated metastasis and improves survival outcome. ( A ) Liver metastases from the Calb2-OE tumor were isolated to establish liver metastasis (LM) organoids. After one week of splenic injection of LM organoids into the C57BL/6 mice, isotype IgG, αCXCL14 (1 mg/kg, intravenously), gemcitabine (25 mg/kg, intraperitoneally) or combined chemotherapy (αCXCL14 + gemcitabine) were injected twice per week for 4 consecutive weeks (top). Animal survival was monitored up to 60 days after injection (bottom). ( B ) Representative IVIS bioluminescence images, bright-field images, and H&E staining for metastatic lesions after 5 weeks of splenic injection of Calb2-OE-LM KPC organoids. Scale bars: 1 cm (left), 2000 μm (middle), 500 μm (right). ( C-D ) Quantification of living imaging, ex vivo liver imaging ( C ) and metastatic nodules ( D ) from B ( n = 6 per group). ( E ) Kaplan-Meier survival curves for mice with KPC liver metastasis-derived organoid xenografts treated with the indicated regimen ( n = 10 per group). ( F ) Schematic diagram illustrating the inflammatory reprogramming mechanism by which CALB2 promotes liver metastasis of PDAC. Error bars, mean ± SD; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant; by one-way ANOVA ( C-D ) or log-rank test ( E )
Article Snippet:
Techniques: Isolation, Injection, Staining, Imaging, Ex Vivo, Derivative Assay
Journal: Cell Reports Medicine
Article Title: Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer
doi: 10.1016/j.xcrm.2023.101162
Figure Lengend Snippet: Metabolite profiling stratifies PDAC into two subtypes (A) PDAC organoid subgrouping based on widely targeted metabolite abundance. Differential metabolites were identified by the Wilcoxon rank-sum test (p < 0.05, fold change > 1.2). Samples and metabolites are displayed as columns and rows, respectively, and the color of each organoid shows the relative abundance of the metabolites. (B) Relative enrichment of the six metabolic ontology classes in class 1 and class 2 organoids, presented as the difference (class 2 versus class 1) in the ssGSEA score. Positive scores represent terms enriched in metabolites with high intensities in class 2. (C) Fractions of labeled metabolites in glycolysis from [U- 13 C 6 ] glucose in representative organoids of class 1 (n = 6) and class 2 (n = 6). (D) Fractions of labeled metabolites in the TCA cycle from [U- 13 C 6 ] glucose in representative organoids of class 1 (n = 6) and class 2 (n = 6). (E and F) Fractions of labeled metabolites in oxidative PPP (E) and nonoxidative PPP (F) from [U- 13 C 6 ] glucose in representative organoids of class 1 (n = 6) and class 2 (n = 6). (G) Heatmap of widely targeted lipidomics assay showing the abundance of differentially lipid metabolites in class 1 (n = 6) and class 2 (n = 6). (H and I) Class 1 (n = 13) and class 2 (n = 15) organoids were exposed to oligomycin, FCCP, and rotenone/antimycin A to measure the oxygen consumption rate (OCR) by XF Cell Mito Stress Test. (J and K) Dose-response curves and normalized area under the curve (AUC) distribution for TVB-3166 (fatty acid synthase inhibitor) on class 1 and class 2. (L and M) Dose-response curves and normalized AUC distribution for Gboxin (inhibitor of oxidative phosphorylation) on class 1 (n = 13) and class 2 (n = 15). (N) Heatmap of RNA sequencing (RNA-seq) showing the expression of differentially expressed genes (DEGs) in glucomet-PDAC (n = 15) and lipomet-PDAC (n = 13) (p was calculated with limma, p < 0.05 and fold change > 1.5). Representative genes associated with lipid or glucose metabolism are shown in the box on the right. (O) Profile plot and heatmap of assay for transposase-accessible chromatin with sequencing (ATAC-seq) results showing the distribution of differential peaks around the transcriptional start site (TSS) of signature genes in lipomet-PDAC (n = 13) and glucomet-PDAC (n = 15). (P) KEGG pathways enriched in the lipomet subtype (left) and glucomet subtype (right) identified by GSEA. The significance of the difference was determined by Student’s t test (∗p < 0.05; ∗∗p < 0.01) (B). Data are presented as the mean values ± SEMs, and statistical significance was computed by unpaired Student’s t test (C–F). Statistical significance was computed by unpaired Student’s t test (I, K, and M). αKG, α-ketoglutarate; G6P, glucose-6-phosphate; 6PG, 6-phosphate gluconate; F6P, fructose-6-phosphate; R5P, ribose 5-phosphate; S7P, sedoheptulose-7-phosphate; E4P, erythrosine 4-phosphate.
Article Snippet:
Techniques: Labeling, Phospho-proteomics, RNA Sequencing, Expressing, Sequencing
Journal: Cell Reports Medicine
Article Title: Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer
doi: 10.1016/j.xcrm.2023.101162
Figure Lengend Snippet: Glucomet-PDAC is associated with worse prognosis and chemoresistance (A) Heatmap of tumors in the Bailey PDAC cohort (n = 55, only squamous and pancreatic progenitor samples were included) split by glucomet and lipomet signature genes. (B) Kaplan-Meier survival curves of the Bailey PDAC cohort showing differential prognosis among patients with different subtypes. (C) Heatmap of tumors in the TCGA PDAC cohort (n = 156, only ductal pancreatic cancer samples were included) split by glucomet and lipomet signature genes. (D) Kaplan-Meier survival curves of the TCGA PDAC cohort showing differential prognosis among patients with different subtypes. (E) Normalized AUC distribution for GEM, 5-FU, OXA, and IRI on glucomet-PDAC (n = 15) and lipomet-PDAC (n = 13). The Z scores of the obtained normalized AUC values are depicted in the heatmap. High values (indicating resistance) are depicted in red, and low values (indicating sensitivity) are depicted in blue. (F) Comparison of AUCs of four agents among the two metabolic subtypes. The boxplot shows the median (central line) and the 25%–75% interquartile range (box limits). (G and H) Representative radiation examination of both the surgical area and liver in lipomet-PDAC (DAC-5 and DAC-18) and glucomet-PDAC (DAC-42 and DAC-22) at the time of diagnosis and 6 months postsurgery. The arrow marks the tumor position. (I–L) 5-FU responsiveness test in the indicated ODX models (n = 6 per group). Tumor volumes measured by calipers at the indicated time points in tumor-implanted mice subjected to treatments with control or 5-FU (25 mg/kg, every 2 days). Statistical significance was computed by log rank test (B and D). Significance was computed by a one-sided paired t test (F). Data are presented as the mean values ± SEMs, and statistical significance was computed by unpaired Student’s t test (I–L). GEM, gemcitabine; 5-FU, 5-fluorouracil; IRI, irinotecan; OXA, oxaliplatin.
Article Snippet:
Techniques: Comparison, Biomarker Discovery, Control
Journal: Cell Reports Medicine
Article Title: Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer
doi: 10.1016/j.xcrm.2023.101162
Figure Lengend Snippet: The GLUT1 and ALDOB drives glucose metabolic reprogramming in glucomet-PDAC (A) Boxplot of ALDOB and GLUT1 expression levels stratified by metabolic subgroup (p was calculated with limma). (B) Scatterplot showing the correlation of lactate intensities and GLUT1 or ALDOB gene expression (Pearson correlation analysis). Each dot represents an individual sample. Color represents the metabolic subgroup (red dot represents glucomet-PDAC, and blue dot represents lipomet-PDAC). (C) Extracellular glucose consumption and lactate secretion were evaluated in representative organoids of glucomet-PDAC (n = 5) and lipomet-PDAC (n = 5). (D and E) Fractions of labeled metabolites in glycolysis (D) and the TCA cycle (E) from [U- 13 C 6 ] glucose in control and GLUT1 knockdown organoids (n = 3 per group). (F and G) Control and GLUT1 knockdown organoids were exposed to rotenone/antimycin A and 2-DG to measure the ECAR at the basal level and compensatory level by the Seahorse XF Glycolytic Rate Assay (n = 3 per group). (H and I) Fractions of labeled metabolites in glycolysis (H) and the TCA cycle (I) from [U- 13 C 6 ] glucose in control and ALDOB -overexpressing organoids (n = 3 per group). (J and K) Control and ALDOB -overexpressing organoids were exposed to rotenone/antimycin A and 2-DG to measure the ECAR at the basal level and compensatory level by the Seahorse XF Glycolytic Rate Assay (n = 3 per group). (C–E, G–I, and K) Data are presented as mean values ± SEMs. Statistical significance was computed by unpaired Student’s t test.
Article Snippet:
Techniques: Expressing, Gene Expression, Labeling, Control, Knockdown
Journal: Cell Reports Medicine
Article Title: Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer
doi: 10.1016/j.xcrm.2023.101162
Figure Lengend Snippet: The GLUT1/ALDOB/G6PD axis drives glucose metabolic reprogramming in glucomet-PDAC (A) Relative G6PD enzyme activity in representative organoids of glucomet-PDAC (n = 6) and lipomet-PDAC (n = 6). (B) Relative G6PD enzyme activity in vector- and ALDOB -overexpressing organoids (n = 3). (C) Relative abundance of oxidative PPP metabolites in control and ALDOB -overexpressing organoids (n = 3). (D and E) Relative abundance of oxidative PPP metabolites in control, GLUT1 knockdown, ALDOB overexpression, GLUT1 knockdown, and ALDOB overexpression organoids (n = 3). (F) Endogenous ALDOB and G6PD interactions in PDAC organoids detected by immunoprecipitation (IP) experiments. (G–I) TCGA patients with PDAC (n = 156) were divided into GLUT1 high / ALDOB low , GLUT1 low / ALDOB high , and others based on GLUT1 and ALDOB expression levels. Samples with expression of GLUT1 in the top 40% and expression of ALDOB in the last 40% were named GLUT1 high / ALDOB low , while samples with expression of ALDOB in the top 40% and expression of GLUT1 in the last 40% were named GLUT1 low / ALDOB high . GSEA enrichment plot for GLUT1 high / ALDOB low group versus GLUT1 low / ALDOB high group of fatty acid metabolism (G), pentose phosphate pathway (H), and glycolysis/gluconeogenesis (I) signature genes. (J) Representative images of immunohistochemical staining show high or low GLUT1 staining and high or low ALDOB staining in PDAC TMA (n = 285). Scale bar, 50 μm. Patients were divided into four groups based on ALDOB and GLUT1 expression levels: ALDOB high (++), ALDOB expression >50%; ALDOB low (+), ALDOB expression <50%; GLUT1 high (++), GLUT1 expression >50%; and GLUT1 low (+), GLUT1 expression <50%. (K) Kaplan-Meier survival curves based on the expression of GLUT1 and ALDOB in 285 patients with PDAC. (L) Summary scheme highlighting the roles of the GLUT1/ALDOB/G6PD axis in glucose reprogramming. Data are presented as the mean values ± SEMs, and statistical significance was computed by unpaired Student’s t test (A–E). Statistical significance was computed by log-rank test (K).
Article Snippet:
Techniques: Activity Assay, Plasmid Preparation, Control, Knockdown, Over Expression, Immunoprecipitation, Expressing, Immunohistochemical staining, Staining
Journal: Cell Reports Medicine
Article Title: Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer
doi: 10.1016/j.xcrm.2023.101162
Figure Lengend Snippet: The GLUT1/ALDOB/G6PD axis contributes to drug resistance (A) Heatmap showing the relative abundance of nucleoside and nucleoside derivatives in glucomet-PDAC (n = 15) and lipomet-PDAC (n = 13). (B) Heatmap showing Pearson correlation coefficients between the RNA expression levels of ALDOB / GLUT1 and nucleoside derivatives. (C and D) DAC-18 (lipomet) and DAC-42 (glucomet) organoids were treated with 5-FU alone or in combination with pyrimidine nucleosides (uridine, cytidine, and thymidine, 240 μM) for 5 days, and cell viability was determined by CellTiter-Glo assays. (E and F) DAC-18 (lipomet) and DAC-42 (glucomet) organoids were treated with PTX alone or in combination with pyrimidine nucleosides (240 μM) for 5 days, and cell viability was determined by CellTiter-Glo assays. (G) Effect of GLUT1 knockdown on 5-FU responsiveness of DAC-34 (glucomet) as determined by CellTiter-Glo assays 120 h after treatment with 5-FU. (H) Effect of ALDOB overexpression on the 5-FU responsiveness of DAC-42 (glucomet) as determined by CellTiter-Glo assays 120 h after treatment with 5-FU. (I) Effect of G6PD knockdown on the 5-FU responsiveness of DAC-42 (glucomet) as determined by CellTiter-Glo assays 120 h after treatment with 5-FU. (J) Effect of ALDOB overexpression on 5-FU responsiveness in the DAC-42 (glucomet) ODX model (n = 6 per group). (K) Effect of pyrimidine nucleotide (240 μM) on 5-FU sensitivity in control and GLUT1 knockdown organoids by CellTiter-Glo assays at 120 h posttreatment. (L) Effect of pyrimidine nucleotide (240 μM) on 5-FU sensitivity in control and ALDOB overexpression organoids by CellTiter-Glo assays at 120 h posttreatment. (M) Effect of R5P (1 mM) on 5-FU sensitivity in control and GLUT1 knockdown organoids by CellTiter-Glo assays at 120 h posttreatment. (N) Effect of R5P (1 mM) on 5-FU sensitivity in control and ALDOB -overexpressing organoids by CellTiter-Glo assays at 120 h posttreatment. (O) Effect of R5P (1 mM) on 5-FU sensitivity in control and G6PD knockdown organoids by CellTiter-Glo assays at 120 h posttreatment. (P and Q) Effect of purine nucleotides (guanosine and adenosine, 200 μM) on 5-FU and GEM sensitivity in control and GLUT1 knockdown organoids by CellTiter-Glo assays at 120 h posttreatment. All dose-responsive curves were performed with 3 technical replicates. Data are presented as the mean values ± SEMs, and statistical significance was computed by unpaired Student’s t test (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001) (C–Q).
Article Snippet:
Techniques: RNA Expression, Knockdown, Over Expression, Control
Journal: Cell Reports Medicine
Article Title: Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer
doi: 10.1016/j.xcrm.2023.101162
Figure Lengend Snippet:
Article Snippet:
Techniques: Sequencing, Recombinant, SYBR Green Assay, RNA Expression, shRNA, Software
Journal: Cell reports. Medicine
Article Title: Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer.
doi: 10.1016/j.xcrm.2023.101162
Figure Lengend Snippet: Figure 4. The GLUT1/ALDOB/G6PD axis drives glucose metabolic reprogramming in glucomet-PDAC (A) Relative G6PD enzyme activity in representative organoids of glucomet-PDAC (n = 6) and lipomet-PDAC (n = 6). (B) Relative G6PD enzyme activity in vector- and ALDOB-overexpressing organoids (n = 3). (C) Relative abundance of oxidative PPP metabolites in control and ALDOB-overexpressing organoids (n = 3).
Article Snippet:
Techniques: Activity Assay, Plasmid Preparation, Control